Back to the Moon: On Becoming a "Cancernaut"

Article

When I unexpectedly joined the cancer program, just before my 50th birthday, I was sure I had the “right stuff” to meet the challenge.

I was 8 years old when we first stepped on the moon. Even at that young age, I knew that it meant we were living in a new world. I watched as the marvels of the space age, and I don’t just mean the wonder that was Tang, sprung up all around us.

As a seven-year survivor of a rare thymic cancer, I feel like that 8-year-old child again as I think about the possible future as we start the new cancer moonshot, proposed by Joe Biden. When I unexpectedly joined the cancer program just before my 50th birthday, I was sure I had the “right stuff” to meet the challenge. However, I was reluctant to join the arms race that is the war on cancer. I’m a pacifist to my core, and the battle against cancer never seemed like a fair fight.

Thanks to the moonshot initiative, I can now adopt a frame of reference for survivorship that feels like a perfect fit. I prefer to think of myself as an explorer, a "cancernaut," if you will, boldly going where many have gone before, only this time with the nation and the world cheering me on.

President Kennedy told the nation that the original moonshot would “serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one which we intend to win.”

How can we expect anything less once we unleash the powers of our new technological age on this deadly disease? How can we not feel the swell of pride in the realization that we stand at a turning point in human history?

Let’s face it, the final frontier is not the depths of space, but the depths of the human experience. For too long, cancer has left its mark on this experience, often having the last word. The attempt to silence this voice through an all-out war has left many of us feeling like refugees, rather than heroes. With this new endeavor, we can rise above our reflexive tendency to fight fire with fire, and, instead, light the flame of inspiration and hope for millions. It makes perfect sense, in a war weary world, to adopt a new paradigm for treating cancer. Imagine the possibilities when we turn rage into enthusiasm—when the summary of a cancer survivor’s life no longer opens with the line, “He lost his battle with cancer,” but instead, “He took living with cancer to new heights.”

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content